All In Biotech

NDA 021920 · Bionpharma

Naproxen Sodium

Naproxen Sodium · Oral

Last checked: Nov 19, 2026Latest source record: Jan 15, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2006

Feb 17, 2006

Approved uses

1

Original approval plus efficacy supplements

Registered trials

356

90 Phase 3, 11 recruiting

FAERS reports

66,594

27,369 serious, 5,059 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Oct 5, 2026.

Uses temporarily relieves minor aches and pains due to: backache muscular aches minor pain of arthritis menstrual cramps headache toothache the common cold temporarily reduces fever

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

1 products under this application
  • NAPROXEN SODIUM · NAPROXEN SODIUM EQ 200MG BASE · CAPSULE, ORAL · Over-the-counter

Clinical trials

Interventional ClinicalTrials.gov studies with "Naproxen" as an intervention, any sponsor and status, largest first.

All 356 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug ineffective11,083
  • fatigue5,089
  • product use issue4,788
  • pain4,754
  • nausea4,276
  • arthralgia4,097
  • headache4,062
  • off label use3,990
  • dizziness3,951
  • diarrhoea3,946
  • rash3,562
  • vomiting3,466

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
2004644
2005773
2006633
2007659
20083,280
20091,851
2010786
20111,013
20121,808
20131,570
20143,690
20157,074
20166,846
20175,779
20184,834
20194,632
20203,587
20213,017
20222,928
20232,813
20243,527
20253,243
20261,605

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Naproxen Sodium (Naproxen Sodium)

2024 spending

$2.8M

Beneficiaries

38,101

69,827 claims

Per beneficiary

$73

$0.69 per unit

View as table
YearSpending
2020$4,598,959
2021$3,694,074
2022$3,258,596
2023$5,373,172
2024$2,780,942

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 1,373 on PubMed

Sponsor: Bionpharma

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.